^
    4d
    Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    tasadenoturev (DNX-2401)
    4d
    Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. (PubMed, J Immunother Cancer)
    Overall, the data demonstrate that RP1 remodels the tumor microenvironment through a combination of direct and indirect effects on both tumor and immune cells, resulting in an overall more inflamed phenotype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CSF2 (Colony stimulating factor 2) • ITGAM (Integrin, alpha M) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    PD-L1 expression
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    7d
    Bevacizumab-Primed Vascular Normalization Enhances Intratumoral Delivery and Efficacy of the tBID-Armed Oncolytic Adenovirus KD01 in Glioma. (PubMed, Front Biosci (Landmark Ed))
    KD01 exerts potent tBID-mediated mitochondrial oncolytic activity against glioma cells. When used as a priming strategy, transient vascular normalization induced by bevacizumab enhanced the intratumoral efficacy of KD01 in an orthotopic glioma model while maintaining a favorable safety profile. These findings support a simple, sequence-dependent combination approach integrating anti-VEGF therapy with oncolytic virotherapy for the treatment of malignant gliomas.
    Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • BID (BH3 Interacting Domain Death Agonist) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Avastin (bevacizumab)
    7d
    MCC-20575: Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC (clinicaltrials.gov)
    P1, N=21, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • cretostimogene grenadenorepvec (CG0070)
    7d
    ARTACUS: Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Replimune Inc. | N=65 --> 90 | Trial completion date: Jan 2028 --> Nov 2029 | Trial primary completion date: Sep 2027 --> Jul 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    15d
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra
    New P2 trial
    |
    tasadenoturev (DNX-2401)
    18d
    RPL-123-01: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (2025-521621-33-00)
    P4, N=41, Not yet recruiting, Replimune Group Inc.
    New P4 trial
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    22d
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Replimune Inc. | Trial primary completion date: Dec 2025 --> Jun 2028
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)
    25d
    Predicting homologous recombination deficiency and treatment responses using a computed tomography-based foundation model: a preclinical study. (PubMed, NPJ Precis Oncol)
    Interpretability analysis indicated the important role of texture heterogeneity in HRD classification. Therefore, these results suggest that FM successfully overcomes the data scarcity in animal studies and enables HRD classification and treatment response prediction from preclinical CT imaging.
    Preclinical • Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    CP-506
    1m
    Phase Ib/II clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of Recombinant Human IL-12 Adenovirus Injection (BioTTT001) in the treatment of patients with recurrent/progressive non-small cell lung cancer with meningeal metastasis (ChiCTR2600117576)
    P1/2, N=42, Completed, Henan Cancer Hospital; Henan Cancer Hospital
    New P1/2 trial
    1m
    Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer. (PubMed, J Immunother Cancer)
    LTX-315; Antitumor immune response; nsPEF; Liver cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Oncopore (ruxotemitide)
    1m
    Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). (PubMed, Clin Cancer Res)
    Immunological fitness, assessed by an anti-adenoviral specific antibody response and higher levels of activated CD8+ NKT-like cells after Delta-24-RGD treatment, may have utility as an early surrogate of a robust systemic immune response that correlates with long-term survival.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    tasadenoturev (DNX-2401)